PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Metamizole→

Metamizole PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
50567-35-6
Molecular formula
C13H17N3O4S
Molecular weight
311.36 g/mol
Drug class
Pyrazolone analgesic and antipyreticnon-opioid pain reliever with spasmolytic activity
Mechanism of action
The exact mechanism is not fully established. Metamizole and its metabolites produce analgesic, antipyretic and spasmolytic effects; proposed actions include central and peripheral modulation of prostaglandin pathways and other pain-signalling mechanisms.
Indications / reported uses
  • Acute severe pain following trauma or surgery
  • Painful colic and other severe pain when alternative measures are inadequate or contraindicated
  • High fever unresponsive to other measures, only in jurisdictions and formulations where authorised; use is restricted in some countries because of agranulocytosis risk

Sources: British Journal of Clinical Pharmacology review (2025) · Metamizole sodium product information (manufacturer dossier; indications subject to national authorisation) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Metamizole PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Metamizole Permitted Daily Exposure (PDE) report (the Metamizole PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Metamizole Occupational Exposure Limit (OEL) report (the Metamizole OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.